A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

BACKGROUND. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gold, Kathryn A., Lee, J. Jack, Harun, Nusrat, Tang, Ximing, Price, Justina, Kawedia, Jitesh D., Tran, Hai T., Erasmus, Jeremy J., Blumenschein, George R., William, William N., Wistuba, Ignacio I., Johnson, Faye M.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201000/
https://ncbi.nlm.nih.gov/pubmed/25170013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0228
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados